Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

Myriad Genetics has a 1-year low of $9.76 and a 1-year high of $29.30. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last issued its earnings results on Tuesday, February 25th.